Register
Combination of axitinib and pembrolizumab safe and effective in patients with advanced renal cell cancer |
Journal Updates
eMediNexus Coverage from: 
Combination of axitinib and pembrolizumab safe and effective in patients with advanced renal cell cancer


comment                   
        



Findings of a study presented February 10, 2018 at the ASCO Genitourinary Cancers Symposium in San Francisco demonstrate the safety and efficacy of axitinib in combination with pembrolizumab in treatment-naive patients with advanced renal cell cancer (aRCC).


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.